Added feature offers cost savings and the ability to reduce carbon footprint, company says.
Suvoda LLC, a clinical trial technology company, announced a new advanced drug optimization feature as part of its latest interactive response technology (IRT) release. According to the company, this feature offers sponsors of clinical drug trials improved drug supply management, delivering cost savings, and helping companies to reduce their carbon footprint. In the past, supply strategies depended on static quantities of initial drug shipments and buffers, often leading to excessive orders to ensure enough medication is available during a trial.
"Suvoda's new enhancement is an example of how we listen to the needs of our customers and deliver tools that help our sponsors and partners," said Lisa Li, director of IRT product management, Suvoda. "We heard from drug supply managers that they were concerned about the impact of drug oversupply across the entire supply chain, including raw materials, manufacturing, storage, shipping, and packing materials. Helping study managers fine-tune supply can maximize trial resources and increase efficiencies."
Reference: Suvoda Introduces Advanced Drug Optimization for IRT to Improve Accuracy of Clinical Trial Drug Supply Management. PR Newswire. October 12, 2023. Accessed October 13, 2023. https://www.prnewswire.com/news-releases/suvoda-introduces-advanced-drug-optimization-for-irt-to-improve-accuracy-of-clinical-trial-drug-supply-management-301951747.html
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.